Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Epilepsy ll: Types01:22

Epilepsy ll: Types

24
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
24
Seizures l: Introduction01:20

Seizures l: Introduction

27
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
27
Seizures: Classification01:13

Seizures: Classification

2.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Seizures ll: Types01:19

Seizures ll: Types

23
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
23
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel epilepsy treatments in clinical development.

Epilepsy & behavior : E&B·2026
Same author

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.

Drugs·2026
Same author

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs.

Epilepsia·2026
Same author

Novel pharmacological therapies in development.

Current opinion in neurology·2026
Same author

Epilepsy, neuroinflammation and cannabidiol What do we know thus far?

Frontiers in pharmacology·2026
Same author

Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.

Neurology·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 23, 2026

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research
04:41

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research

Published on: October 13, 2023

2.1K

Epilepsy: new advances.

Solomon L Moshé1, Emilio Perucca2, Philippe Ryvlin3

  • 1Saul R Korey Department of Neurology, Dominick P Purpura Department of Neuroscience and Department of Pediatrics, Laboratory of Developmental Epilepsy, Montefiore/Einstein Epilepsy Management Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, NY, USA.

Lancet (London, England)
|September 28, 2014
PubMed
Summary
This summary is machine-generated.

Epilepsy impacts millions globally, causing disability and high costs. Despite advances in understanding and treatment, many patients remain resistant to therapies, highlighting critical gaps in care and research.

More Related Videos

Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

Related Experiment Videos

Last Updated: Apr 23, 2026

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research
04:41

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research

Published on: October 13, 2023

2.1K
Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

Area of Science:

  • Neurology
  • Clinical Medicine
  • Public Health

Background:

  • Epilepsy affects 65 million individuals worldwide, posing significant challenges in disability, mortality, comorbidities, stigma, and economic burden.
  • Recent decades have seen progress in understanding epilepsy's pathophysiology and prognostic factors.
  • This has led to updated definitions, diagnostic criteria, and classification systems for epilepsy.

Purpose of the Study:

  • To review the current landscape of epilepsy management and identify persistent challenges.
  • To highlight advances in understanding and treatment while acknowledging unmet needs.

Main Methods:

  • Literature review of recent advances in epilepsy research and clinical practice.
  • Analysis of treatment outcomes for antiepileptic drugs and surgical interventions.
  • Assessment of existing gaps in knowledge, diagnosis, treatment, and patient support.

Main Results:

  • Despite a substantial increase in antiepileptic drugs over 20 years, approximately one-third of patients exhibit drug resistance.
  • Epilepsy surgery offers significant seizure freedom for over half of patients but is underutilized.
  • Persistent gaps remain in knowledge, diagnosis, treatment, advocacy, education, legislation, and research.

Conclusions:

  • Significant challenges persist in managing epilepsy, particularly drug-resistant cases.
  • Current treatment modalities, including surgery, are not reaching all eligible patients.
  • Urgent, concerted actions are required to address the multifaceted challenges in epilepsy care and research.